



You are invited to submit an application to meet with the OneVentures Healthcare Team at AusBiotech 2017

OneVentures is pleased to invite emerging healthcare companies to apply for a private meeting with members of the OneVentures \$170M Healthcare Fund III team. Selected biomedical companies will meet privately with members of the OneVentures Investment Team, for an opportunity to pitch their projects and companies. This is a fantastic opportunity to discuss your company or research project, and discover growth and partnership opportunities.

OneVentures is looking for companies commercialising medical devices, diagnostics and pharmaceuticals. Make the most of your day and apply now for a private meeting with members of the OneVentures Healthcare Team, on Friday 27 October 2017 at AusBiotech 2017.

Please submit the following information by 9 October 2017:

- Company/project name
- Contact details
- A 200-word description of the company including target market, solution overview and stage of development
- A summary of capital raised to date (if any) and capital required (if known)

Program

OneVentures briefing session

Friday 27 October 2-2.30pm Skyway Room 1

OneVentures one-on-one meetings (**by appointment only**)

Thirty minute appointments between 2.30-5.30pm



Supported by



OneVentures at Ausbiotech 2017.

Apply now for a private meeting.

27 October 2017

About OneVentures

OneVentures is an Australian venture capital firm with \$320M under management launching its first fund in 2010. A global growth focus drives investment selection with portfolio companies addressing multi-billion dollar problems. Existing healthcare sector portfolio companies include Hatchtech, Vaxxas, Clinical Genomics Technologies and Prota Therapeutics.

OneVentures recently launched its \$170M Healthcare Fund III, which is focused on investing in therapeutics, devices or diagnostics at or near clinical development with a clear commercial, regulatory and reimbursement pathway; and well defined value inflection and exit points on deal entry. The OneVentures' team has deep experience in driving opportunities through the FDA regulatory process and commercialising biomedical innovations in global markets.

The fund launched in December 2016 and is licenced under the Commonwealth government's Biomedical Translation Fund (BTF) programme. The BTF programme was established to provide a pool of public and private funds for investment in promising biomedical innovations with commercialisation potential managed by leading Australian venture firms. OneVentures was granted an \$85 million license supported by matching capital from its private investor network. The government funding provides benefits to investors both during the investment phase and on realisation.

The fund will invest \$10 to \$20 million in Australian domiciled companies commercialising medical devices, drugs in clinical development or diagnostics.

For more on OneVentures, visit their website: www.one-ventures.com

Know someone who should pitch to OneVentures?

We're searching for the
companies of tomorrow.